Exploring Coherus BioSciences, Inc. (CHRS) Investor Profile: Who’s Buying and Why?

Have you ever wondered who the major players are behind Coherus BioSciences, Inc. (CHRS), and what their investment decisions might signal? As of April 2025, 252 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 74,656,844 shares. Could these institutional holdings influence the company's strategic direction, especially as they navigate a transformative phase, shifting towards becoming an innovative oncology company? With key financial results from 2024 showing annual net revenue increased by 4% to $267.0 million, driven by a 62% year-over-year increase in UDENYCA® net revenue, understanding the investor profile becomes even more crucial. Let's dive into who these investors are and what might be driving their interest in Coherus BioSciences.

Coherus BioSciences, Inc. (CHRS) Who Invests in Coherus BioSciences, Inc. (CHRS) and Why?

Understanding the investor profile of Coherus BioSciences, Inc. (CHRS) involves examining the diverse range of entities and individuals that hold its stock, and their motivations for doing so. These investors typically include retail investors, institutional investors, and hedge funds, each bringing different investment strategies and objectives.

Key Investor Types:

• Retail Investors: These are individual investors who buy and sell shares for their own accounts. Their investment decisions are often based on personal research, recommendations from financial advisors, or general market sentiment.
• Institutional Investors: This category includes entities such as mutual funds, pension funds, insurance companies, and investment banks. These institutions manage large sums of money on behalf of others and typically have a longer-term investment horizon.
• Hedge Funds: These are investment partnerships that use pooled funds and employ various strategies to generate active returns for their investors. Hedge funds are known for their flexibility and ability to invest in a wide range of assets, often with a focus on maximizing returns through more aggressive strategies.

Investment Motivations:

Investors are attracted to Coherus BioSciences, Inc. (CHRS) for a variety of reasons, generally centered around the company's potential for growth and its position within the competitive pharmaceutical market. Some key motivators include:

• Growth Prospects: Investors often look at the company's pipeline of biosimilar products and their potential to capture market share. Positive clinical trial results and regulatory approvals can significantly boost investor confidence.
• Market Position: Coherus BioSciences, Inc. (CHRS)'s standing in the biosimilars market, its partnerships, and its ability to compete with established pharmaceutical companies are critical factors. A strong market position can provide a competitive edge and drive revenue growth.

Investment Strategies:

The strategies employed by investors in Coherus BioSciences, Inc. (CHRS) can vary widely depending on their investment goals and risk tolerance:

• Long-Term Holding: Many institutional investors adopt a long-term holding strategy, banking on the company's sustained growth and the increasing adoption of biosimilars. This approach involves holding the stock for an extended period, often several years, to benefit from the company's long-term potential.
• Short-Term Trading: Hedge funds and some retail investors may engage in short-term trading, seeking to profit from short-term price fluctuations driven by news events, earnings reports, or market trends. This strategy involves buying and selling shares within a shorter timeframe, sometimes within days or weeks.
• Value Investing: Some investors may view Coherus BioSciences, Inc. (CHRS) as undervalued based on its assets, potential earnings, and market position. Value investors seek to buy stocks that they believe are trading below their intrinsic value, with the expectation that the market will eventually recognize their true worth.

For additional insights into Coherus BioSciences, Inc. (CHRS), you might find this resource helpful: Coherus BioSciences, Inc. (CHRS): History, Ownership, Mission, How It Works & Makes Money

Coherus BioSciences, Inc. (CHRS) Institutional Ownership and Major Shareholders of Coherus BioSciences, Inc. (CHRS)

Institutional ownership often provides insights into a company's stability and long-term prospects. Examining the major shareholders of Coherus BioSciences, Inc. (CHRS) can reveal the level of confidence that large financial institutions have in the company's future.

Here's an overview of the top institutional investors in Coherus BioSciences, recent changes in their holdings, and the potential impact these investors have on the company.

Based on the latest available data, the top institutional investors in Coherus BioSciences, Inc. (CHRS) include:

• BlackRock Inc.
• The Vanguard Group Inc.
• State Street Corp.
• FMR LLC
• Geode Capital Management LLC

These institutions hold a significant percentage of the company's outstanding shares, reflecting their substantial investment and belief in its potential.

Changes in institutional ownership can indicate shifts in sentiment towards a company. Recent activity in Coherus BioSciences, Inc. (CHRS) includes:

• Some institutions increasing their stakes, signaling confidence in the company’s growth prospects.
• Others decreasing their positions, potentially due to portfolio adjustments or concerns about the company’s performance.

Monitoring these changes can provide valuable insights into the evolving perspectives of major investors.

Institutional investors can significantly influence a company's stock price and strategic direction. Their actions can lead to:

• Increased trading volume and price volatility when they make large trades.
• Greater scrutiny of company performance, as institutional investors often demand accountability and strategic clarity.
• Potential for long-term stability if institutions maintain significant holdings, demonstrating sustained confidence in the company.

The presence and activity of these large investors play a crucial role in shaping market perceptions and influencing company decisions.

Here is a detailed table of the institutional ownership of Coherus BioSciences, Inc. (CHRS):

These figures reflect holdings as of the latest reporting periods and provide a snapshot of institutional investment in Coherus BioSciences, Inc. (CHRS).

To gain more insights into Coherus BioSciences, Inc. (CHRS), you might find this resource helpful: Coherus BioSciences, Inc. (CHRS): History, Ownership, Mission, How It Works & Makes Money

Coherus BioSciences, Inc. (CHRS) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Coherus BioSciences, Inc. (CHRS) provides valuable insights into the company's stability, growth potential, and strategic direction. Examining who is investing, their motivations, and recent activities can significantly inform stakeholders about the overall sentiment surrounding the company.

While specific, real-time details on all investors and their precise influence can fluctuate and may not always be publicly available, we can look at the general types of investors and their potential impact based on typical investment behaviors.

Institutional investors represent a significant portion of Coherus BioSciences, Inc. (CHRS)'s shareholder base. These entities include mutual funds, pension funds, hedge funds, and insurance companies. Their investment decisions are driven by in-depth research and analysis, and their actions can have a substantial impact on the company’s stock price and strategic direction.

Here's a general overview of how different investor types might influence Coherus BioSciences, Inc. (CHRS):

• Mutual Funds: Often hold large positions and invest for long-term growth. Their presence can signal confidence in the company's prospects.
• Hedge Funds: May take more active roles, seeking short-term gains through various trading strategies. They might also push for corporate changes to unlock value.
• Pension Funds: Typically have a long-term investment horizon and look for stable, reliable returns. Their investment can provide stability to the stock.
• Activist Investors: These investors purchase significant stakes in a company to influence its management and strategy. Their involvement can lead to major changes in corporate policy, operations, or even leadership.

Recent moves by key investors, such as increasing or decreasing their positions, can provide signals about their confidence in Coherus BioSciences, Inc. (CHRS). Large-scale acquisitions of shares may indicate a bullish outlook, while significant divestments could suggest concerns about the company's future performance.

Keeping track of these activities offers clues into the expectations and potential future trajectory of Coherus BioSciences, Inc. (CHRS). For instance, if a well-known healthcare fund significantly increases its stake, it might reflect a strong belief in the company's pipeline or market strategy.

The ownership structure and investor activity can also influence company decisions. A large institutional investor might engage with management on issues like R&D spending, clinical trial strategies, or potential mergers and acquisitions. Activist investors might publicly advocate for specific changes, putting pressure on the company to act.

Here is a general illustrative table, note that the actual data may vary and is subject to change:

For more insights into Coherus BioSciences, Inc. (CHRS), you might find this link helpful: Coherus BioSciences, Inc. (CHRS): History, Ownership, Mission, How It Works & Makes Money

Coherus BioSciences, Inc. (CHRS) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to Coherus BioSciences, Inc. (CHRS) is crucial for assessing the company's current position and future prospects. Several factors influence how major shareholders perceive CHRS, and how the stock market responds to significant investor activities.

Coherus BioSciences, Inc. (CHRS) has a substantial institutional ownership base. As of April 2025, 252 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 74,656,844 shares. Major shareholders include:

• Vanguard Group Inc
• BlackRock, Inc.
• Point72 Asset Management, L.P.
• Rubric Capital Management LP
• Tang Capital Management Llc
• VTSMX - Vanguard Total Stock Market Index Fund Investor Shares
• Group One Trading, L.p.
• Kohlberg Kravis Roberts & Co. L.P.
• IWM - iShares Russell 2000 ETF
• Geode Capital Management, Llc

Institutional ownership accounts for 56.51% of the company, representing 116 million total shares outstanding and a total value of holdings of $73 million.

Recent trading data indicates some shifts in institutional positions. For instance, in Q3 2024, TEMASEK HOLDINGS (PRIVATE) LTD reduced its holdings by 5,818,802 shares, while in Q4 2024, POINT72 ASSET MANAGEMENT, L.P. increased its position by 5,283,292 shares.

The Fund Sentiment Score, which gauges how much funds are buying a stock, uses a quantitative model considering increases in disclosed owners and changes in portfolio allocations. This score helps identify companies with high levels of institutional accumulation.

Recent market reactions to Coherus BioSciences have been mixed. On March 10, 2025, following the release of Q4 2024 earnings, the stock rose by 0.93% in after-hours trading, reaching $1.05. The Q4 2024 earnings report showed a revenue of $54.1 million, exceeding the forecasted $44.15 million, and an EPS of -$0.28, slightly better than the expected -$0.30. The company's strategic shifts, including divestitures and focus on oncology, have influenced these market reactions.

However, the share price has shown considerable volatility. As of April 17, 2025, the share price was $1.12, a 48.62% decrease from $2.18 on April 22, 2024. Despite this, the price increased by 50.90% from the prior week, reflecting short-term gains amidst long-term challenges.

Analysts' perspectives on Coherus BioSciences, Inc. (CHRS) vary, but generally lean towards a positive outlook. According to 4 analysts, the average rating for CHRS stock is 'Strong Buy.' The 12-month stock price forecast is $5.38, which is an increase of 380.36% from the latest price. The forecasts range from a low of $1.50 to a high of $7.00.

An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.

Analysts' insights often highlight the company's strategic moves and potential growth areas. For instance, Coherus's focus on oncology and the development of drugs like LOQTORZI and casdozokitug are seen as promising. Additionally, the divestiture of the UDENYCA franchise for $483.4 million upfront and potential milestone payments up to $75 million has been viewed positively, as it reduces debt and provides a $250 million cash buffer for oncology programs.

However, some analysts also point out financial challenges. Coherus operates with a substantial debt burden, including a $38.7 million term loan maturing in 2029 and $230 million in convertible debt due in 2026. Revenue growth is projected to decline, attributed to the monetization of assets, which impacts the revenue growth outlook.

Here's a summary of Coherus BioSciences' recent financial performance:

Overall, the investor sentiment towards Coherus BioSciences, Inc. (CHRS) appears cautiously optimistic, driven by strategic shifts towards oncology and improved financial structuring, but tempered by existing debt and market volatility. Analyst perspectives vary, reflecting both the potential upside and the inherent risks in the biopharmaceutical industry.

For more information on Coherus BioSciences, Inc. (CHRS), you can also read: Coherus BioSciences, Inc. (CHRS): History, Ownership, Mission, How It Works & Makes Money